Panacea Biotec (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Panacea Biotec Limited |
|||
|
Price: ₹429.10 | ||
| 52 Week Low: ₹112.35 52 Week High: ₹490.55 |
|||
| Market Capital: 812.55 Crore (Smallcap) | |||
| Healthcare -> Biotechnology | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Panacea Biotec Share Price Target For 2024
- 1.1.1: Panacea Biotec Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Panacea Biotec Share Price Target For 2025
- 1.2.1: Panacea Biotec Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Panacea Biotec Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Panacea Biotec Brief Company Overview
- 4: Panacea Biotec Financial Performance
- 4.0.1: Is Panacea Biotec A Good Buy For Long Term?
To predict the Panacea Biotec's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Panacea Biotec Share Price Target For 2024
The line chart displays the monthly closing prices of Panacea Biotec with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Panacea Biotec shares in 2024, see the table below.
Panacea Biotec Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 449.0 (+4.63%) | Price Action: May 2021 High |
| 2024 Target 2 | 444.39 (+3.56%) | Fibonacci Extension Level 23.60% |
| 2024 Target 1 | 439.5 (+2.42%) | Price Action: 19 Dec 2024 Low |
| Current Price | 429.10 | Panacea Biotec's share price as of 23 Dec 2024 |
| Stop Loss 1 | 424.16 (-1.15%) | Price Action: May 2006 High |
| Stop Loss 2 | 418.13 (-2.56%) | Price Action: Feb 2007 High |
| Stop Loss 3 | 412.29 (-3.92%) | Price Action: Jul 2021 High |
Short-Term Technical Outlook
Current Technical Position: Panacea Biotec is showing mixed momentum signals near key moving averages.
Key Technical Level: The 25-day moving average at ₹440.93 serves as the nearest technical reference point.
Historical Returns: 3-month: +49.1% | 6-month: +234.47% | 1-year: +166.93%
Panacea Biotec Share Price Target For 2025
The line chart displays the monthly closing prices of Panacea Biotec with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Panacea Biotec shares in 2025, see the table below.
Panacea Biotec Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 694.25 (+61.79%) | Price Action: Chart |
| 2025 Target 2 | 681.31 (+58.77%) | Price Action: Chart |
| 2025 Target 1 | 674.56 (+57.2%) | Fibonacci Extension Level 64.90% |
| Current Price | 429.10 | Panacea Biotec's share price as of 23 Dec 2024 |
| Stop Loss 1 | 370.87 (-13.58%) | Price Action: Dec 2007 High |
| Stop Loss 2 | 364.79 (-14.99%) | Price Action: Aug 2021 High |
| Stop Loss 3 | 357.7 (-16.64%) | Price Action: 14 Nov 2024 High |
Long-Term Technical Outlook
52-Week Range Analysis: Panacea Biotec is currently trading near its 52-week high of ₹490.55, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +166.93% | 3-year: +125.61% | 5-year: +301.64%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Panacea Biotec Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹429.10 | ||
| 2024 | ₹408.93 | -4.7% | ₹415.06 |
| 2025 | ₹771.32 | +88.61% | ₹782.89 |
| 2026 | ₹1,095.81 | +42.06% | ₹1,112.25 |
| 2027 | ₹1,410.35 | +28.7% | ₹1,431.51 |
| 2028 | ₹1,890.34 | +34.03% | ₹1,918.70 |
| 2029 | ₹2,241.88 | +18.59% | ₹2,275.51 |
| 2030 | ₹2,594.36 | +15.72% | ₹2,670.70 |
| 2031 | ₹2,854.44 | +10.02% | ₹2,897.26 |
| 2032 | ₹3,123.81 | +9.43% | ₹3,310.12 |
| 2033 | ₹3,738.01 | +19.66% | ₹3,794.08 |
| 2034 | ₹4,074.82 | +9.01% | ₹4,135.94 |
| 2035 | ₹4,417.39 | +8.4% | ₹4,569.61 |
| 2036 | ₹4,613.08 | +4.42% | ₹4,723.55 |
| 2037 | ₹4,837.26 | +4.85% | ₹5,194.69 |
| 2038 | ₹5,585.67 | +15.47% | ₹5,669.46 |
| 2039 | ₹5,695.01 | +1.95% | ₹5,993.80 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Panacea Biotec Brief Company Overview
Panacea Biotec Limited: A Healthcare Pioneer with Global Reach Established in 1984, Panacea Biotec is a renowned biotechnology company headquartered in India. Its core business encompasses research, development, manufacturing, and marketing of pharmaceutical...
formulations and vaccines. Panacea Biotec boasts a diverse product portfolio catering to various therapeutic areas, including pain management, diabetes, cardiovascular management, oncology, and gastro-intestinal care. The company also holds a strong position in the vaccine market, offering pneumococcal, dengue, typhoid, and universal flu vaccines. Panacea Biotec has expanded its global presence, exporting its products to over 36 countries, including the US, Europe, and the Asia-Pacific region. It has collaborations with leading organizations like the Russian Direct Investment Fund and CEPI to develop vaccines against COVID-19 and other viral threats. The company's commitment to innovation and patient care has earned it a strong reputation in the healthcare industry. Panacea Biotec remains dedicated to addressing unmet medical needs and improving global health.Panacea Biotec Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 812.55 Crore | Market valuation of Panacea Biotec's shares. |
| Revenue (TTM) | 559.16 Crore | Total revenue generated by Panacea Biotec over the past twelve months. |
| Net Income (TTM) | -1.17 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | -2.97% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | -0.21% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+5.8% | Change in revenue compared to the previous quarter. |
| Earnings Growth (YOY Quarterly) |
+8.38% | Change in earnings compared to the same quarter last year. |
| Debt-to-Equity (D/E) Ratio |
2.5 | Company's total debt divided by total shareholder equity. |
| Total Debt | 20.99 Crore | Sum of Panacea Biotec's current & long-term financial obligations. |
| Total Cash | 185 Crore | Total amount of liquid funds available to Panacea Biotec. |
| Beta | 0.75 | Beta is less than 1 indicating that the Panacea Biotec's price is less volatile than the market. |
Is Panacea Biotec A Good Buy For Long Term?
Panacea Biotec's recent performance paints a mixed picture. While the company boasts a healthy cash balance of 185 Crore and a modest debt of 20.99 Crore, its recent financial performance is concerning. The company reported a net loss of 1.17 Crore for the last 12 months, with a profit margin of -0.21. Additionally, the stock has experienced negative returns over the past 3, 6, and 12 months. While its 5-year return is slightly positive, its 3-year return is significantly negative. Given this information, Panacea Biotec is not a good buy for long-term investors at this time.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
